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Transcription is activated by signal-induced protein–protein interaction between transcription fac-
tors on regulatory elements positioned near their target genes. Here, we tested the utility of the b-
catenin binding RNA aptamer as a tool for studying protein–protein interaction within transcription
complex and for modulating expression of a target gene. The RNA aptamer bound Armadillo repeats
of b-catenin and was effective in disrupting protein–protein interaction between b-catenin and
nuclear factor-jB (NF-jB) p50. In addition, the RNA aptamer effectively reduced tumor necrosis fac-
tor-a induced transcription from the promoter of C-reactive protein regulated by b-catenin and NF-
jB p50. Taken together, b-catenin binding RNA aptamer was an effective regulator of b-catenin and
NF-jB p50 mediated transcription.
Structured summary:
MINT-7023762: beta catenin (uniprotkb:P35222) physically interacts (MI:0218) with NF-kappa-B p50 (uni-
protkb:P19838) by anti bait coimmunoprecipitation (MI:0006)
MINT-7023938: beta catenin (uniprotkb:P35222) binds (MI:0407) to TCF-1 (uniprotkb:P36402) by pull
down (MI:0096)
MINT-7023862: beta catenin (uniprotkb:P35222) binds (MI:0407) to NF-kappa-B p50 (uniprotkb:P19838)
by pull down (MI:0096)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Transcription is regulated by complex and dynamic binding of
transcription factors on the target gene. Protein–protein interac-
tions between transcription factors might also play a critical role
in the initiation of transcription. For a complex transcription factor
that is capable of interaction with multitude of other factors, spe-
ciﬁc tools are required to decipher the roles of the transcription
factor and to disrupt the protein–protein interactions on its target
promoters.
b-Catenin is an example of such a complex multifunctional pro-
tein that plays critical roles in cell adhesion as well as in Wnt-acti-
vated transcription [1]. When b-catenin levels rise, it accumulates
in the nucleus, where it interacts with T-cell factor (TCF) family of
proteins to activate the transcription of various target genes. Inchemical Societies. Published by E
active protein; TNF-a, tumoraddition to TCF proteins, b-catenin is known to interact with many
other proteins; especially, it binds to diverse proteins responsible
for speciﬁc transcriptional regulation and chromatin remodeling
in the nucleus [2,3]. Some examples of protein recognition by b-
catenin have been extensively studied [4]. We have previously re-
ported the identiﬁcation of b-catenin as a co-activator that might
provide nuclear factor (NF)-jB p50 subunit with a transactivation
domain [5].
NF-jB/Rel is also a complex transcription factor that controls
innate immunity, inﬂammation, or cell survival depending on its
activation signaling pathway [6–8]. Functional speciﬁcities of NF-
jB subunits (p50, p52, p65/Rel A, Rel B, and c-Rel) depend on the
formation of subunit dimers and subunit exchange [9]. Therefore,
an understanding of the functional speciﬁcity of NF-jB requires
knowledge of protein–protein interaction with other transcription
factors such as b-catenin. We and others have shown that the gene
encoding C-reactive protein (CRP), a major human acute phase re-
sponse factor, is regulated by NF-jB p50 and b-catenin [5,10,11].
Most signiﬁcantly, transcription of the CRP gene depends upon
the interaction between NF-jB p50 and b-catenin following
inﬂammatory signal activation by tumor necrosis factor-a (TNF-a).lsevier B.V. All rights reserved.
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two factors is expected to disrupt the transcription of CRP gene.
Aptamers are molecules that possess high afﬁnity and speciﬁc-
ity to their targets [12]. Since RNA aptamers tightly bind to partic-
ular protein, they might act as inhibitors by interfering protein–
protein interaction between their own target and other proteins
in the cells. In this regard, speciﬁc b-catenin binding aptamers
might be useful tools to analyze interactions between b-catenin
and other transcription factors such as TCF and NF-jB p50, as well
as for modulation of b-catenin transcriptional activity. We have
previously developed RNA aptamers for TCF and b-catenin proteins
and have shown they bind target proteins with high afﬁnity and
speciﬁcity [13–15]. Especially, b-catenin binding RNA aptamer
(pU6-b-cat-Apt) is promising as a tool for disrupting protein–pro-
tein interaction between b-catenin and TCF proteins, because of
its high afﬁnity (Kd = 10 nM) in vitro and inhibition of b-catenin-
mediated transcription and tumorigenesis in colon cancer cell lines
[14,15].
Presently, we utilized pU6-b-cat-Apt as a proof-of-concept
model to study the complex protein–protein interaction
between b-catenin and NF-jB p50, and for modulating transcrip-
tion of their target gene, CRP. We found that the pU6-b-cat-Apt
was effective in disrupting protein–protein interaction between
b-catenin and NF-jB p50; these disruptions reduced the
expression of CRP mRNA.2. Materials and methods
2.1. Reagents and antisera
Recombinant human TNF-a, phosphatase inhibitor cocktail,
protease inhibitor cocktail, and anti-FLAG M2 mouse monoclonal
antibody (F3165) were purchased from Sigma–Aldrich (St. Louis,
MO). Anti-p50 mouse monoclonal antibody (sc-8414) and Anti-
TCF-4 rabbit polyclonal antibody (sc-13027) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-b-catenin mouse
monoclonal antibody (610154) was purchased from BD Biosci-
ences (Franklin Lakes, NJ). Anti-TCF-1 rabbit polyclonal antibody
was generated by KOMA Biotech (Seoul, Korea). Synthetic CRP oli-
gonucleotides (sense strand; 50-TAGTGGCGCAAACTCCCTTACT-30,
anti-sense strand; 50-AGTAAAGGGAGTTTGCGCCACT-30) were gen-
erated by Bioneer (Seoul, Korea).2.2. Cloning and expression of GST-b-catenin proteins
Bacterial expression vectors for recombinant b-catenin protein
were obtained by polymerase chain reaction (PCR) ampliﬁcation
of the pCAN-b-catenin plasmid [14]. GST-Arm 1-12 (amino acids
129–695) was ampliﬁed with primers containing BamHI (50 pri-
mer, 50-TGCGGATCCCACAGATGCTGAAACAT-30) and EcoRI (30 pri-
mer, 50-GCGAATTCAGTCTCATTCCAAGCCAT-30) restriction sites.
The PCR products were cloned into pBluesriptII-SK vector using
these restriction sites. The inserts were excised using BamHI
and XhoI, and ligated to a pGEX-5X-1 vector to produce the GST-
b-catenin fusion vector. GST-DArm 1–9 (amino acids 1–13 and
552–780) was generated by digesting pGEX-b-catenin with NcoI,
followed by self-ligation. Recombinant GST-fusion proteins were
produced in BL21 (DE3) cells. The cells were incubated with
0.1 mM IPTG at 37 C for 3 h and lysed in extraction buffer
(50 mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT
and 2% Triton X-100). The released GST-fusion proteins were puri-
ﬁed using glutathione-Sepharose 4B beads (Amersham, Bucking-
hamshire, UK), dialyzed extensively against phosphate buffered
saline, and quantiﬁed by a commercial Bradford assay (Bio-Rad,
Hercules, CA).2.3. Plasmids
Human NF-jB p50 expression clone was kindly provided by Dr.
Young Mee Kim (Asan Medical Center) and constructed as FLAG-
p50 as previously described [5]. The 125 CRP Luciferase reporter
was kindly provided by Dr. Irving Kushner (Case Western Reserve
University). Cloning of pSUPER-b-catenin and pSUPER-p50
plasmids was previously reported [5]. Sequences for shRNAs are
following: pSUPER-b-catenin (50GATCCCGTGGGTGGTATAGA-
GGCTCTTCAAGAGAGAGCCTCTATACCACCCACTTTTTGGAAA-30 and
50AGCTTTTCCAAAAAGTGGGTGGTATAGAGGCTCTCTCTTGAAGAGC-
CTCTATACCACCCACGG-30) and pSUPER-p50 (50GATCCCTATTA-
GAGCAACCTAAACATTCAAGAGATGTTTAGGTTGCTCTAATATTTTTG-
GAAA-30 and 50AGCTTTTCCAAAAATATTAGAGCAACCTAAACATCTC-
TTGAATGTTTAGGTTGCTCTAATAGG-30). Stable b-catenin (S37A)
plasmid was constructed as previously reported [15]. GST- NF-jB
p50 plasmid was composed of human NF-jB p50 cDNA (nucleo-
tides 52–1205, Genbank/Bank Accession NM_003998) in the
pGEX-4T vector (Pharmacia Biotech, Piscataway, NJ). GST-TCF-1
plasmid was composed of murine TCF-1 cDNA (nucleotides 190–
1101, Genbank/Bank Accession X61385) in the pGEX-4T vector.
2.4. Construction of pU6-b-cat-Apt and pU6-NC-Apt
RNA aptamers were expressed in pTZU6+27 vector (pU6-Vec-
tor) containing U6 promoter and a portion of U6 RNA with strong
stem–loop structure [16]. Using this vector system, stable small
RNA can be expressed with highly structured stem-loops at both
ends. The DNA sequence encoding the RNA aptamer was inserted
between strong stem loops in the U6. To insert the aptamer se-
quences into pU6 vector, the DNA sequence of the aptamer was
ampliﬁed from the pUC19-aptamer clone [14]. The ampliﬁed
fragment was digested with SalI and XbaI, and cloned into the
same site of the pU6-Vector, generating pU6-b-cat-Apt [14] and
pU6-NC-Apt [17]. The sequence of b-cat-Apt is 50-GGG-
ACGCGUGGUACCAGGCCGAUCUAUGGACGCUAUAGGCACACCGGA-
UACUUUAACGAUUGGCUAAGCUUCCGCGGGGAUC-30, showing the
selected sequences in bold and the ﬂanking deﬁned ends are in
plain letters. pU6-NC-Apt was used as a negative control, which
has the aptamer for nucleocapsid (NC) protein of human immuno-
deﬁciency virus type-1 in the same vector [17].
2.5. Electrophoretic mobility shift assay (EMSA)
CRP oligonucleotides were end-labeled with [c-32P] ATP using
T4 polynucleotide kinase. Nuclear extracts were incubated with
2 lg of poly (dI–dC) in binding buffer (5 mM Tris–HCl, pH 7.4,
50 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% glycerol) for 10 min at
37 C. The end-labeled probe was added, the mixtures incubated
for 10 min at 37 C, and aliquots run on 4% native polyacrylamide
gels in 1X TAE buffer. The gels were dried and subjected to autora-
diography. For RNA-EMSA, RNA molecules were transcribed with
T7 RNA polymerase and puriﬁed on a 10% polyacrylamide/7 M urea
gel. In vitro transcribed RNA was labeled with [c-32P] UTP and
incubated with the GST-b-catenin proteins. Following incubation,
RNA-protein complexes were resolved on 5% native gels. The gels
were dried and subjected to autoradiography.
2.6. Cell culture, transfection, and luciferase assay
The 293T and HepG2 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS)
(BRL Life Technologies, Carlsbad, CA). HepG2 cells were cultured
in minimum essential medium containing 10% FBS. Transfection
of cells was performed using LipofectAMINE transfection reagent
(Invitrogen, Carlsbad, CA). For luciferase assays, the cells were
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cat-Apt or pU6-NC-Apt. After 24 h of incubation, cells were cul-
tured under serum-free conditions for 2 h followed by treatment
with 30 ng/ml TNF-a for 8 h. pSUPER-b-catenin or pSUPER-p50
was transiently transfected to knock-down p50 or b-catenin pro-
tein. After 72 h of transfection, cells were cultured under serum-
free conditions for 2 h followed by treatment with TNF-a (30 ng/
ml) for 8 h before harvest. Luciferase activity was determined with
a luciferase assay system (Promega, Madison, WI) with a GLOMAX-
20 luminometer (Turner Biosystems, Sunnyvale, CA).
2.7. Immunoprecipitation
Whole-cell extracts from 293T cells were centrifuged at
12000 rpm for 15 min to obtain clear lysates and incubated with
anti-b-catenin antibodies overnight, followed by incubation with
protein G-agarose beads (BRL Life Technologies) for 3 h to facilitate
immunoprecipitation.
2.8. GST–pull-down assay
Glutathione-sepharose beads were washed with TEN100 buffer
(20 mM Tris, pH 7.4, 0.1 mM EDTA, and 100 mMNaCl). GST-b-cate-
nin or GST was immobilized on the beads and washed four times
with 100 volumes of TEN100 buffer. Immobilized GST-b-catenin
(100 nM) or GST (100 nM) was incubated with puriﬁed TCF-
1(100 nM) or p50 proteins (100 nM) for 1 h at 4 C and washed four
times with TEN100 buffer. Bound proteins were eluted by boiling in
the sample buffer and visualized using Western blot analysis.
2.9. RT-PCR and real-time PCR analysis
Total cellular RNA was isolated from cells with TRIzol (Invitro-
gen), reverse transcribed with M-MuLV Reverse Transcriptase
and used in the PCR reactions. The level of expression of the
pU6-b-cat-Apt RNA in 293T cells was estimated by RT-PCR using
the pU6-b-cat-Apt-speciﬁc primer sets, U6-F1 (50-TGATGTCGAC-
TAGGGACGCGTGGT-30) and U6-R1 (50-GACTCTAGAGGATCCCCG-
30), which produce a 144 bp PCR product. Real-time PCR was done
with a Rotor-Gene RG-3000A system (Corbett Research). Reactions
were ampliﬁed using the CRP forward and reverse primers [5] and
an LC FastStart reaction mix SYBR Green I kit (Roche), according to
the manufacturer’s instructions. PCR ampliﬁcation cycle was at
denaturation at 95 C for 5 s, annealing at 54 C for 10 s (GAPDH)
or at 50 C (CRP), and extension at 72 C for 15 s. Quantiﬁcation
was carried out with the Rotor Gene 6 software (Corbett Research).
Relative levels of CRP mRNA were expressed as the ratio of com-
parative threshold cycle (CT) to internal control glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) mRNA.
2.10. Northern blot assay
For Northern blot analysis, total cellular RNAwas extracted. RNA
samples (5 lg/lane) were separated on denaturing polyacrylamide
gels and blotted to nylon membranes. The blots were cross-linked
with UV and hybridized with DIG-labeled RNA probes (Roche). A
DIG Luminescent Detection kit (Roche) was used for detection.3. Results
3.1. pU6-b-cat-Apt stably expresses in the cells and binds armadillo
repeats of b-catenin
Since effective suppression of target gene is achieved by using a
human U6 small nuclear RNA promoter driven nuclear RNA apt-amer, we utilized b-catenin binding RNA aptamer in U6 vector
(pU6-b-cat-Apt) [14,15]. Secondary structure of pU6-b-cat-Apt is
predicted by mfold and shown in Fig. 1A. We ﬁrst characterized
the expression and stability of pU6-b-cat-Apt by Northern blot
and RT-PCR analyses, showing high level expression of stable tran-
scripts over ﬁve days in 293T cells (Fig. 1B and C). It also showed
that expression of pU6-b-cat-Apt is highly restricted to nucleus
(Fig. 1D).
Previous structural analyses of b-catenin have revealed that
Armadillo repeat region of b-catenin forms a superhelical rod-like
structure made of 12 repeats [18–21]. To map the b-catenin pro-
tein binding sites of pU6-b-cat-Apt, we expressed a series of de-
leted b-catenin proteins. RNA-EMSA (Fig. 1E) with recombinant
b-catenin proteins (Fig. 1F) showed that the pU6-b-cat-Apt
strongly bound to full-length b-catenin as well as to an armadillo
domain with whole 12 repeats (Arm 1–12). Some of unbound
RNA is still remained in theses lanes, probably by low stability of
RNA–protein complex under this gel condition. Especially, deletion
of repeats 1–9 (Delta Arm 1–9) completely abolished the binding
suggesting that the binding site of pU6-b-cat-Apt on b-catenin
overlapped with that of TCF binding.
3.2. pU6-b-cat-Apt disrupts protein–protein interaction between
b-catenin and NF-jB p50
Previous experiment suggested that pU6-b-cat-Apt might also
disrupt the protein–protein interaction between b-catenin and
other b-catenin binding proteins. Even though it was proposed that
b-catenin interacts with NF-jB in cancer cells [22–24], whether the
interaction between these two transcription factors is direct phys-
ical interaction has not to date been rigorously addressed. Since
armadillo repeats of b-catenin provide a binding surface to many
proteins, we envisioned that the proposed interaction between b-
catenin and NF-jB could also be mediated by armadillo repeats.
Since the p65 subunit of NF-jB interacts physically with b-catenin
[22–24], we also tested whether the p50 subunit of NF-jB directly
interacts with b-catenin by use of a GST pull-down assay. The
observations revealed that b-catenin clearly interacted with NF-
jB p50 (Fig. 2A), as has been shown for TCF-1 interaction with b-
catenin as a positive control.
To test if pU6-b-cat-Apt could inhibit the physical interaction
between NF-jB p50 and b-catenin in the cells, we co-expressed
FLAG-tagged NF-jB p50 and pU6-b-cat-Apt and performed co-
immunoprecipitation assays (Fig. 2B). It clearly demonstrated that
protein–protein interaction between NF-jB p50 and b-catenin is
disrupted by increasing amount of pU6-b-cat-Apt, but not by
pU6-NC-Apt that harbors the aptamer for nucleocapsid protein of
HIV-1 in pU6-Vector as a negative control.
3.3. b-catenin and NF-jB p50 is required for the expression of CRP
We have previously reported that NF-jB p50 is responsible for
the activation from the non-consensus jB site in the CRP promoter
(Fig. 3A) [5]. In addition, since we presently showed that NF-jB
p50 can directly interact with b-catenin, we conﬁrmed the role of
NF-jB p50 and b-catenin on CRP expression. We overexpressed
two proteins and measured the luciferase activity from the CRP
promoter in 293T cells as a model cell line (Fig. 3B). Signiﬁcant in-
crease of luciferase activity was observed when NF-jB p50 and b-
catenin were co-expressed. To establish the critical roles of the NF-
jB p50 and b-catenin in TNF-induced CRP promoter activity,
expression of two proteins were knocked down using pSUPER-shR-
NAs (Fig. 3C). To conﬁrm the efﬁcacy of the shRNAs, we performed
Western blot analyses with anti-p50 and anti-b-catenin antibodies
(data not shown). Knock-down of p50 resulted in a substantial
reduction of CRP promoter activity, which can be explained by
Fig. 1. Stable nuclear expression of pU6-b-cat-Apt and its binding to armadillo repeats. (A) Predicted secondary structure of the pU6-b-cat-Apt as determined by the mfold
program. Box indicates nucleotides from the selected sequence. (B) Northern blot analysis of the pU6-b-cat-Apt. 293T cells were transfected either with pU6 vector or with
the pU6-b-cat-Apt, and total cellular RNA was isolated after transfection. Lanes 1–3, total RNA (1 lg) frommock, pU6-b-cat-Apt or pU6 vector transfected cells; lane 4, In vitro
transcribed (IVT) b-cat- Apt (10 ng) as a control. pU6-b-cat-Apt is 164 nts; IVT-b-cat-Apt is 80 nts. (C) Expression of the pU6-b-cat-Apt for a period of 5 days as shown by RT-
PCR analysis. GAPDH was shown as a control. (D) Nuclear localization of pU6-b-cat-Apt. 293T cells were transfected with the pU6-b-cat-Apt (0.5 lg) and fractionated. RNA
was isolated from the nuclear extract (N.E) or cytoplasmic extract (C.E), and the expression of RNA Aptamer was determined by RT-PCR analysis. (E) RNA-EMSAs with the
radiolabled RNA aptamer (200 pM) and b-catenin proteins. Lane 1, labeled RNA only; lane 2, GST (1 lM); lane 3, full length b-catenin (200 nM); lane 4, Arms 1–12 (200 nM)
andDArms 1–9 (200 nM). Locations of bound (B) and unbound (U) aptamers are indicated. (F) Coomassie Blue staining of the GST fused b-catenin proteins (1 lg of protein per
lane).
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scription. In addition, reduction of CRP promoter activity was also
observed when shRNA for b-catenin was introduced. These results
suggest that NF-jB p50 and b-catenin are important components
of TNF-a induced CRP promoter activity.
To test if NF-jB p50 and b-catenin could activate CRP tran-
scription by binding to the non-consensus jB site in the CRP pro-
moter (Fig. 3A), oligonucleotides derived from CRP promoter at
79/50 representing the non-consensus jB site were utilized.
When the nuclear extract was made from FLAG tagged NF-jB
p50 and b-catenin transfected 293T cells, two DNA bound bands
were evident (Fig. 3D). To identify the speciﬁc proteins participat-
ing in the complex, nuclear extracts were incubated with FLAG or
b-catenin antibody. The lower and upper bands were supershifted
by anti-FLAG antibody, while the upper band was supershifted
only with anti b-catenin antibody, which suggested that b-catenin
protein bound to CRP oligonucleotide by interaction with the NF-
jB p50 protein.3.4. pU6-b-cat-Apt suppresses TNF-a induced CRP
The observation that b-catenin contributes to the transcrip-
tional activation of NF-jB p50 on the CRP promoter suggested that
b-catenin might participate as a transcriptional co-activator of NF-
jB p50. We further tested whether the pU6-b-cat-Apt could inhibit
TNF-a-induced CRP transcription using the 125 CRP Luc reporter
assay (Fig. 4A) and RT-PCR analysis (Fig. 4B). To gain further insight
on TNF-a-induced CRP expression in more natural cells we utilized
hepatocyte cell line HepG2 cells, because acute inﬂammation in-
duced plasma CRP is primarily produced by hepatocytes (Fig. 4).
Luciferase assay clearly showed that TNF-a induced the expression
of the CRP gene in HepG2 cells. However, co-expression of pU6-b-
cat-Apt inhibited TNF-a-induced transcriptional activity of the CRP
promoter, but not by a negative control pU6-NC-Apt (Fig. 4A). Sig-
niﬁcant reduction of CRP mRNA was also evident when the pU6-b-
cat-Apt was co-expressed in TNF-a treated HepG2 cells as shown
by RT-PCR and real-time PCR analyses (Fig. 4B and C).
Fig. 2. Blockage of protein–protein interaction between b-catenin and NF-jB p50 by pU6-b-cat-Apt. (A) GST-pull-down assay for the protein–protein interaction between b-
catenin and NF-jB p50. GST-b-catenin was immobilized on glutathione-Sepharose beads and incubated with puriﬁed TCF-1 proteins or puriﬁed NF-jB p50 proteins. The
bound proteins were eluted and visualized using Western blot analysis. b-Catenin bound proteins were analyzed with anti-TCF-1 or anti-NF-jB p50 antibodies. Anti-b-
catenin antibody was used as a control for pull-down efﬁciency and anti-TCF-1 antibody was used as a positive control for interaction. (B) Co-immunoprecipitation assay of b-
catenin and NF-jB p50 in the presence of pU6-b-cat-Apt or pU6-NC-Apt. FLAG-tagged NF-jB p50 expression construct was co-transfected with increasing amount (100, 500
and 1000 ng) of pU6-b-cat-Apt or pU6-NC-Apt. After 48 h, immunoprecipitation (IP) was performed with anti-b-catenin antibody. Immunoblotting (IB) was performed on the
precipitates with anti-b-catenin or anti-FLAG antibody. Input represented 10% of whole cell extract.
Fig. 3. Requirement of NF-kB p50 and b-catenin in TNF-a induced CRP expression. (A) Diagram of125 CRP luciferase reporter. NF-jB p50 binding non-consensus jB site and
C/EBP site are shown. (B) Luciferase assay of the 125 CRP promoter in 293T cells. Cells were transfected with the 125 CRP luciferase reporter (200 ng) and co-transfected
with either NF-jB p50 (300 ng) and/or stable b-catenin expression vectors (300 ng). After 24 h, luciferase activity was determined, normalized with b-gal activity, and is
shown as Relative Luciferase Activity. Results are the average of three independent experiments. (C) 293T cells were transfected with the 125 CRP luciferase reporters
(200 ng) and co-transfected with either pSUPER vector (400 ng), pSUPER-p50 shRNA (p50, 400 ng) or pSUPER-b-catenin shRNA (b-catenin, 400 ng). After 72 h, cells were
incubated with or without TNF-a (30 ng/ml) for 9 h. Luciferase activity was determined, normalized with b-gal activity and is shown as Relative Luciferase Activity. Results
are the average of three independent experiments. (D) EMSA assay with the oligonucleotide derived from non-consensus jB site within 125 CRP promoter. 293T cells were
transfected with a FLAG-tagged NF-jB p50 (500 ng) and S37A b-catenin (500 ng) expression vectors. After 24 h, nuclear extracts were prepared and incubated with the
synthetic CRP oligonucleotides as well as anti-FLAG or anti-b-catenin antibody. Normal mouse IgG was used as a control.
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Fig. 4. Reduction of TNF-a-induced CRP expression by pU6-b-cat-Apt. (A) Luciferase assay in the presence of pU6 vector, pU6-b-cat-Apt or pU6-NC-Apt. HepG2 cells were co-
transfected with the 125 CRP luciferase reporter (400 ng) and either U6 vector (pU6), pU6-b-cat-Apt (1 lg) or pU6-b-NC-Apt (1 lg). After 24 h, cells were incubated with or
without TNF-a (30 ng/ml) for 6 h. Luciferase activity was determined and normalized with b-gal activity and is shown as Relative Luciferase Activity. Results are the average
of three independent experiments. (B) RT-PCR analysis of CRP mRNA following pU6-b-cat-Apt (1 lg) or pU6-NC-Apt (1 lg) transfection in HepG2 cells. Cells were transfected
for 48 h and were incubated with or without TNF-a (30 ng/ml) for 6 h. GAPDH was used as a control. (C) Real-time PCR analysis of CRP mRNA in the presence of 1 lg each of
pU6 vector, pU6-b-cat-Apt or pU6-NC-Apt in HepG2. After 48 h, cells were incubated with or without TNF-a (30 ng/ml) for 6 h. GAPDH mRNA was used as a control and the
relative expression of the CRP mRNA is plotted. (D) Schematic diagram depicting the proposed role of pU6-b-cat-Apt in the modulation of TNF-a induced CRP expression.
pU6-b-cat-Apt might reduce the CRP expression by interfering with the protein–protein interaction between b-catenin and NF-jB p50.
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Considering the high afﬁnity of TCF for b-catenin (Kd = 8–30 nM
depending on literature) and extensive binding surface between
two proteins, development of speciﬁc inhibitors capable of disrupt-
ing the interaction between TCF and b-catenin has been challeng-
ing [18–21]. However, the large binding surface of a RNA aptamer
offers a unique property to extensively interact with the target pro-
tein, thereby enhancing the possibility that even an extensive sur-
face interaction between proteins can be disrupted. Presently, we
demonstrate that b-catenin binding RNA aptamer (pU6-b-cat-
Apt) can disrupt protein–protein interaction between b-catenin
and NF-jB p50. Most signiﬁcant ﬁnding here is that pU6-b-cat-
Apt is an effective tool for inhibiting TNF-a induced CRP expression
which are mediated by protein–protein interaction between b-
catenin and NF-jB p50 (Fig. 4). Since b-catenin was known as a
transcriptional co-activator for DNA-bound TCF/LEF family pro-
teins, it might act similarly on DNA-bound NF-jB p50. Therefore,
it is likely that the binding of pU6-b-cat-Apt on armadillo repeats
must act by disrupting DNA-bound transcription factor complexes
thereby repressing the transcription from CRP promoter as pro-posed in Fig. 4D. Since such an interaction might be critical for
other oncogenic gene expression in cancer cells [25], the use of
RNA aptamers has potential as a therapeutic tool. Strengthening
this suggestion is our previous demonstration that the presently
used RNA aptamer reduces the colony forming potential of colon
cancer cells [14,26]. It will be of the utmost interest to analyze
the gene expression proﬁle modulated by RNA aptamer in cancer
cells to see it any other b-catenin target genes are regulated. We
hope to further extend the utility of the RNA aptamer for potential
anti-cancer therapeutics.
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